Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT
LBL-024 DOSED FIRST PATIENT IN MELANOMA PHASE IB/II TRIAL OF OPAMTISTOMIG

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Company.

The Company is pleased to announce that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating Opamtistomig (LBL-024, PD-L1/4-1BB bispecific antibody) as monotherapy or in combination with other agents for the first-line treatment of advanced melanoma.

Phase Ib/II Trial Initiated

The Phase Ib/II, multi-center clinical trial is led by Professor Chen Yu (陳譽) of Fujian Cancer Hospital (福建省腫瘤醫院), with participation from multiple hospitals across China. The trial aims to evaluate Opamtistomig's efficacy and safety in advanced melanoma as monotherapy or in combination regimens.

ABOUT LBL-024

LBL-024 is a bispecific antibody simultaneously targeting PD-L1 and 4-1BB. It stands as the first treatment targeting 4-1BB receptor to have reached registrational stage globally for extra-pulmonary neuroendocrine carcinoma (EP-NEC). LBL-024 also has the potential to become the first drug approved for treating advanced EP-NEC. Leveraging our proprietary X-body™ platform, LBL-024 features an optimal 2:2 structural design and can relieve PD-1/L1 immunosuppression and enhance 4-1BB regulated T-cell activation, achieving a synergistic effect in eliminating tumors and demonstrating greater potential for broad-spectrum cancer treatment compared to PD-1/L1 inhibitors.

The Company obtained an approval from the National Medical Products Administration (NMPA) for a single-arm registrational trial in April 2024 and received the Breakthrough Therapy Designation (BTD) for LBL-024 in treating late-line advanced EP-NEC from the NMPA in October 2024, as well as the Orphan Drug Designation (ODD) in treating neuroendocrine carcinoma (NEC) from the U.S. Food and Drug Administration (FDA) in November 2024.

Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: The Company cannot guarantee that it will be able to develop, or ultimately market, LBL-024, successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
Chairman, Executive Director and Chief Executive Officer

Nanjing, PRC, September 12, 2025

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Ni Jia as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.